Published in Clin Cancer Res on October 27, 2014
Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer. Obstet Gynecol (2015) 0.93
Effects of BRCA1/2 on Ovarian and Breast Cancer Survival--Letter. Clin Cancer Res (2015) 0.87
Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis. Oncotarget (2016) 0.83
Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival. Transl Oncol (2015) 0.81
The development of PARP inhibitors in ovarian cancer: from bench to bedside. Br J Cancer (2015) 0.80
Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression. PLoS One (2016) 0.77
BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget (2016) 0.77
Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. Onco Targets Ther (2017) 0.77
Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. Cancer Prev Res (Phila) (2016) 0.76
Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. Fam Cancer (2016) 0.76
Tumor characteristics and prognosis in familial breast cancer. BMC Cancer (2016) 0.75
Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis. Oncotarget (2016) 0.75
Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients. PLoS One (2016) 0.75
Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore) (2016) 0.75
Effects of BRCA1/2 on Ovarian and Breast Cancer Survival--Response. Clin Cancer Res (2015) 0.75
Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival. Ecancermedicalscience (2016) 0.75
BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study. J Ovarian Res (2016) 0.75
Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer? J Gastrointest Oncol (2016) 0.75
Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma. Cureus (2017) 0.75
The association between prognosis of breast cancer and first-degree family history of breast or ovarian cancer: a systematic review and meta-analysis. Fam Cancer (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
Operating characteristics of a rank correlation test for publication bias. Biometrics (1994) 47.97
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med (2009) 35.37
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med (1998) 19.07
Evaluating non-randomised intervention studies. Health Technol Assess (2003) 9.69
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
Brca1 controls homology-directed DNA repair. Mol Cell (1999) 7.82
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
Systematic reviews of evaluations of prognostic variables. BMJ (2001) 6.69
Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med (2007) 4.25
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol (2012) 3.86
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA (2000) 3.69
Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol (2008) 3.46
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer (2007) 1.84
Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol (2011) 1.78
Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol (2000) 1.71
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer (2007) 1.58
Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res (1999) 1.51
Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst (2012) 1.48
Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer (2005) 1.45
Emerging roles of BRCA1 alternative splicing. Mol Pathol (2003) 1.41
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer (2011) 1.32
Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res (1997) 1.32
Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer (2007) 1.30
Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer (2003) 1.27
Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol (2013) 1.26
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol (2000) 1.23
Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland. Int J Cancer (2001) 1.15
Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res Treat (2010) 1.10
Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. BMC Cancer (2010) 1.04
Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Res Treat (2006) 1.03
The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis. PLoS One (2014) 1.02
Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci Rep (2014) 1.02
Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur J Surg Oncol (2001) 1.02
Survival and tumor characteristics of German hereditary breast cancer patients. Breast Cancer Res Treat (2000) 1.01
BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. Cancer Treat Rev (2001) 1.00
Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol (2004) 0.99
Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res (2002) 0.97
Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics (2012) 0.89
Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia. BMC Cancer (2009) 0.88
BRCA2 gene mutations in Greek patients with familial breast cancer. Hum Mutat (2002) 0.86
BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer. Ann Oncol (2013) 0.84
Tumour diploidy and survival in breast cancer patients with BRCA2 mutations. Breast Cancer Res Treat (2013) 0.83
BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups. Ann Oncol (2013) 0.80
Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer. JAMA (2012) 0.80
Effects of BRCA1/2 on Ovarian and Breast Cancer Survival--Response. Clin Cancer Res (2015) 0.75